Kronos Bio Inc Ordinary Shares KRON
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KRON is a good fit for your portfolio.
News
-
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
-
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
-
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
-
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
Trading Information
- Previous Close Price
- $0.95
- Day Range
- $0.96–1.00
- 52-Week Range
- $0.73–2.29
- Bid/Ask
- $0.95 / $1.04
- Market Cap
- $57.69 Mil
- Volume/Avg
- 100 / 381,614
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.72
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 62
- Website
- https://www.kronosbio.com
Comparables
Valuation
|
Metric
|
KRON
|
CGEM
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.35 | 1.79 | 0.97 |
Price/Sales | 8.72 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KRON
|
CGEM
|
EQRX
|
|---|---|---|---|
Quick Ratio | 7.01 | 16.60 | 18.43 |
Current Ratio | 7.24 | 17.07 | 18.78 |
Interest Coverage | — | — | — |
Quick Ratio
KRON
CGEM
EQRX
Profitability
|
Metric
|
KRON
|
CGEM
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −32.61% | −24.60% | −15.72% |
Return on Equity (Normalized) | −41.80% | −25.95% | −16.71% |
Return on Invested Capital (Normalized) | −40.34% | −29.67% | −21.31% |
Return on Assets
KRON
CGEM
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ggvzcshsn | Hxmn | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Zlppwgrd | Nzyjvn | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hjszrcgz | Nddmfw | $99.5 Bil | |
MRNA
| Moderna Inc | Shdvjhng | Jhc | $38.8 Bil | |
ARGX
| argenx SE ADR | Dzklpgz | Hqvp | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Kxglnmv | Xjnmh | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jbbcmxfp | Gtdcyh | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Whwbxpj | Pmwpdf | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lpxhnvck | Pzrgxh | $12.5 Bil | |
INCY
| Incyte Corp | Fddjlph | Vntspn | $11.6 Bil |